CCB Principal CSI Innovative Drugs Industry ETF

Norges Bank Increases Stake in Pharmaron by 254,500 Shares, Latest Holding Ratio Reaches 7.07%

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Hangzhou Topmed to Hold AGM on June 9 to Vote on Special Resolution for A-Share Buyback

JPMorgan Cuts Tigercat Profit Forecasts and Target Price to 39 HKD

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

Controlling Shareholder Investigated, Tigermed's 1 Billion Buyback Fails to Stop Stock Decline

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

China Renaissance Global Fund Increases Stake in Tigermed by 719,300 Shares on May 14 for HKD 25.84 Million

Schroders PLC Reduces Stake in Tigermed by 579,300 Shares on May 14

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Fosun Pharma: Expected to submit NDA by year-end

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

BeiGene's Brukinsa Approved by FDA

Norges Bank Increases Holding of Tigermed to 813,800 Shares

159638

159558

516320

159835

515120

588200

512480

Since 2026, foreign institutions' research on A-share listed companies has continued to heat up. According to Wind statistics, as of April 10 this year, foreign institutions have conducted nearly 1,400 research visits to Shanghai Stock Exchange companies, covering about 190 companies, with a focus on sectors such as semiconductors, high-end equipment, smart hardware, and innovative drugs. Against the backdrop of increasing global uncertainty, the intensive research by foreign institutions on A-share companies highlights their emphasis on and recognition of the safety and stability of Chinese assets. (Securities Times)

36Kr

Harvest CSI High-End Equipment Subdivision 50 ETF

E Fund CSI Semiconductor Material & Equipment Thematic ETF

ChinaAMC CSI Equipment Industry ETF

GF CSI Innovative Drugs Industry ETF

Harvest SSE STAR Chip ETF

GTJA Allianz CSI All Share Semiconductors & Semiconductor Equipment ETF

In the year to date, foreign institutions have conducted nearly 1,400 research visits to companies listed on the Shanghai Stock Exchange, focusing primarily on sectors such as semiconductors and high-end equipment

512010

589720

159286

560900

516080

159622

517380

520970

159992

159316

516060

New State Council policies explicitly establish a 'price protection period' for innovative drugs, allowing high-level innovative drugs to set their own prices during the initial launch phase and enjoy this protection period. Centralized procurement will not touch innovative drugs, while a diversified commercial insurance payment system simultaneously opens up new space. Stimulated by this news, the A-share innovative drug sector surged strongly in the afternoon session, with multiple stocks hitting the limit up. Brokerage firms point out that the convergence of earnings realization, valuation repair, and policy catalysts may have ushered in a new wave of market activity for the innovative drug sector

Wallstreetcn

E Fund CSI 300 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

Penghua CNI HK Connect Innovative Drugs ETF

ChinaAMC CSI Biotechnology Theme ETF

J.P.Morgan Asset Management CSI Brand Name Drug Industry ETF

E Fund CSI Innovative Drugs ETF

Eastmoney Fund CSI SH-HK-SZ Brand Name Drug Industry ETF

Tianhong Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drugs Selected 50 ETF

Harvest CSI Hong Kong Connect Innovative Drugs ETF

Yinhua CSI Innovative Drugs Industry ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern CSI Brand Name Drug Industry ETF

ICBCCS CSI Brand Name Drug Industry ETF

PKU HEALTHCARE

SL PHARM

HPGC

HISUN

Hvsen Biotech

YKYY

Staidson BioPharm

Hengrui Pharma

HENGRUI PHARMA

BeOne Medicines

BEONE MEDICINES

InnoCare Pharma

INNOCARE

RemeGen

REMEGEN

Shenwan Hongyuan

SWHY

SHCF

Beigene

SWHYHK

Explosive Growth in Innovative Drugs: Top-Level Pricing Mechanism Reform, Who Will Be the Biggest Winner?

800医药

510660

520690

In the first quarter of 2026, China's innovative drug industry performed exceptionally well, with the total amount of out-licensing transactions exceeding USD 60 billion, nearly half of the total for the entire year of 2025. The National Medical Products Administration approved 13 innovative drugs for market launch, of which 6 are first-in-class drugs, covering key disease areas. The total number of innovative drugs under research in China reached 4,751, accounting for 33.7% of the global total, with over 45% in several cutting-edge fields. China has become the world's largest country for innovative drugs under research, with transaction volume accounting for 49% of the global total

腾讯新闻 - 财经

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng SCHK Innovative Drug Select ETF

Yinhua CNI HK Connect Innovative Drugs ETF

JPMorgan Chase

INNOVENT BIO

Eli Lilly

CSPC PHARMA

AstraZeneca

CITIC Securities Co., Ltd.

CITIC SEC

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

AstraZeneca PLC

Mindset Observation Institute: In the first quarter, China's innovative drugs delivered an exciting report card

The General Office of the State Council issued "Several Opinions on Improving the Price Formation Mechanism for Pharmaceuticals," establishing a pricing governance logic for drugs centered on clinical value and innovation level. Experts indicate that this policy provides stable expectations and autonomous pricing space for the innovative drug industry, promoting industry profitability. In the first quarter, the total amount of external licensing transactions for innovative drugs exceeded USD 60 billion, and the innovative drug sectors in both the A-share and Hong Kong markets rebounded strongly. Despite the favorable policy, the contradictions between medical insurance payments and hospital usage still need to be resolved

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

Ping An CSI HK Equities Medical and Health Integration ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

CICC

From "Medical Insurance Negotiation Price Reduction" to "Self-Determined Pricing Protection": The drug price formation mechanism directly addresses the biggest pain point, and innovative drugs welcome a return to value

520880

On April 10th, the innovative drug sector saw a slight rebound, with the Hang Seng SCHK Innovative Drug Index and the CSI Innovative Drugs Industry Index both rising by 0.5%. Against this backdrop, the E Fund Innovative Drug ETF (159316) recorded a net subscription scale of 17 million shares throughout the day. CMB International pointed out that the biopharmaceutical industry has become an emerging pillar industry, with policy dividends continuing to be released. Breakthroughs in AI pharmaceutical technology and cooperation in the overseas expansion of Chinese innovative drugs are forming a dual resonance, and the industry's fundamentals are expected to accelerate positively

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

The innovative drug sector shows slight signs of recovery. What innovative drug-related ETFs are under E Fund?

On April 9th, despite the innovative drug sector experiencing fluctuations and weakness, the Hang Seng SCHK Innovative Drug Index fell by 1.1%, and the CSI Innovative Drugs Industry Index dropped by 1.3%. However, the E Fund Hang Seng SCHK Innovative Drug ETF (159316) saw a net subscription of 17 million shares against the trend. Guosen Securities pointed out that the government work report has listed biomedicine as an emerging pillar industry for the first time, which is expected to promote industrial innovation and support the development of biomedicine

The innovative drug sector is experiencing fluctuations and adjustments, while E Fund Hang Seng SCHK Innovative Drug ETF (159316) has seen net subscriptions against the trend

300149

On April 1st, all three major A-share indices rose by more than 1%, with innovative drug concept stocks collectively increasing, and multiple stocks such as ChemPartner hitting the daily limit. The upcoming 2026 American Association for Cancer Research Annual Meeting has become a catalyst for market enthusiasm. Huayuan Securities pointed out that China's pharmaceutical industry has completed the transition from generics to innovation, with innovative drugs becoming a new engine for industry growth. Future investments should focus on innovative drug companies with global competitiveness and cutting-edge technology directions

ChemPartner

April starts with a bang, the innovative drug concept collectively explodes, ChemPartner hits the 20% daily limit up

161122

The CSI Innovative Drugs Industry Index surged 11% over the past week. Brokerages believe the innovative drug sector is in a stage of "earnings realization, valuation repair, and conference catalysis." Multiple biopharmaceutical companies have achieved historic turnarounds, with fundamentals improving. In the first quarter of this year, the total amount of China's innovative drug out-licensing reached nearly $57 billion, already exceeding the full-year level of 2024. The upcoming AACR and ASCO annual meetings, with intensive clinical data disclosures, are expected to provide catalysts

E Fund CSI WD Biotechnology Index Fund(LOF)-A

Wanjia CSI Hong Kong Connect Innovative Drugs ETF

Invesco Great Wall CSI Hong Kong Connect Innovative Drug ETF

Innovative Drugs Break Out Again After Six Months, Leading Companies Enter Intensive Harvest Period; Has the Profit Inflection Point Arrived?

CCB Principal CSI Innovative Drugs Industry ETF(159835.SZ)

In the year to date, foreign institutions have conducted nearly 1,400 research visits to companies listed on the Shanghai Stock Exchange, focusing primarily on sectors such as semiconductors and high-end equipment

Explosive Growth in Innovative Drugs: Top-Level Pricing Mechanism Reform, Who Will Be the Biggest Winner?

Mindset Observation Institute: In the first quarter, China's innovative drugs delivered an exciting report card

From "Medical Insurance Negotiation Price Reduction" to "Self-Determined Pricing Protection": The drug price formation mechanism directly addresses the biggest pain point, and innovative drugs welcome a return to value

The innovative drug sector shows slight signs of recovery. What innovative drug-related ETFs are under E Fund?